Klassen Preston 4
4 · Regulus Therapeutics Inc. · Filed Jan 17, 2024
Insider Transaction Report
Form 4
Klassen Preston
DirectorPresident & Head of R & D
Transactions
- Award
Stock Option (Right to Buy)
2024-01-12+120,000→ 120,000 totalExercise: $1.30Exp: 2034-01-11→ Common Stock (120,000 underlying)
Footnotes (1)
- [F1]The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.